Glenmark Pharmaceuticals Limited

NSEI:GLENMARK Rapporto sulle azioni

Cap. di mercato: ₹414.3b

Glenmark Pharmaceuticals Gestione

Gestione criteri di controllo 1/4

Glenmark Pharmaceuticals Il CEO è Glenn Saldanha, nominato in Jan2001, e ha un mandato di 26.25 anni. la retribuzione annua totale è ₹ 168.61M, composta da 80% di stipendio e 20% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.35% delle azioni della società, per un valore di ₹ 1.46B. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 1.7 anni e 6.7 anni.

Informazioni chiave

Glenn Saldanha

Amministratore delegato

₹168.6m

Compenso totale

Percentuale dello stipendio del CEO80.0%
Mandato del CEO24yrs
Proprietà del CEO0.4%
Durata media del management1.7yrs
Durata media del Consiglio di amministrazione6.7yrs

Aggiornamenti recenti sulla gestione

This Is Why Glenmark Pharmaceuticals Limited's (NSE:GLENMARK) CEO Compensation Looks Appropriate

Sep 21
This Is Why Glenmark Pharmaceuticals Limited's (NSE:GLENMARK) CEO Compensation Looks Appropriate

Shareholders Will Probably Hold Off On Increasing Glenmark Pharmaceuticals Limited's (NSE:GLENMARK) CEO Compensation For The Time Being

Sep 23
Shareholders Will Probably Hold Off On Increasing Glenmark Pharmaceuticals Limited's (NSE:GLENMARK) CEO Compensation For The Time Being

Recent updates

Is Glenmark Pharmaceuticals (NSE:GLENMARK) A Risky Investment?

Dec 17
Is Glenmark Pharmaceuticals (NSE:GLENMARK) A Risky Investment?

Pinning Down Glenmark Pharmaceuticals Limited's (NSE:GLENMARK) P/S Is Difficult Right Now

Oct 26
Pinning Down Glenmark Pharmaceuticals Limited's (NSE:GLENMARK) P/S Is Difficult Right Now

This Is Why Glenmark Pharmaceuticals Limited's (NSE:GLENMARK) CEO Compensation Looks Appropriate

Sep 21
This Is Why Glenmark Pharmaceuticals Limited's (NSE:GLENMARK) CEO Compensation Looks Appropriate

Glenmark Pharmaceuticals (NSE:GLENMARK) Is Paying Out A Dividend Of ₹2.50

Sep 06
Glenmark Pharmaceuticals (NSE:GLENMARK) Is Paying Out A Dividend Of ₹2.50

Calculating The Fair Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)

Aug 06
Calculating The Fair Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)

Does Glenmark Pharmaceuticals (NSE:GLENMARK) Have A Healthy Balance Sheet?

Jun 16
Does Glenmark Pharmaceuticals (NSE:GLENMARK) Have A Healthy Balance Sheet?

Is Glenmark Pharmaceuticals Limited (NSE:GLENMARK) Expensive For A Reason? A Look At Its Intrinsic Value

May 08
Is Glenmark Pharmaceuticals Limited (NSE:GLENMARK) Expensive For A Reason? A Look At Its Intrinsic Value

Glenmark Pharmaceuticals (NSE:GLENMARK) Takes On Some Risk With Its Use Of Debt

Mar 09
Glenmark Pharmaceuticals (NSE:GLENMARK) Takes On Some Risk With Its Use Of Debt

Is Glenmark Pharmaceuticals (NSE:GLENMARK) Using Too Much Debt?

Dec 07
Is Glenmark Pharmaceuticals (NSE:GLENMARK) Using Too Much Debt?

Shareholders Will Probably Hold Off On Increasing Glenmark Pharmaceuticals Limited's (NSE:GLENMARK) CEO Compensation For The Time Being

Sep 23
Shareholders Will Probably Hold Off On Increasing Glenmark Pharmaceuticals Limited's (NSE:GLENMARK) CEO Compensation For The Time Being

Glenmark Pharmaceuticals (NSE:GLENMARK) Will Pay A Dividend Of ₹2.50

Sep 17
Glenmark Pharmaceuticals (NSE:GLENMARK) Will Pay A Dividend Of ₹2.50

Glenmark Pharmaceuticals (NSE:GLENMARK) Has Announced A Dividend Of ₹2.50

Aug 30
Glenmark Pharmaceuticals (NSE:GLENMARK) Has Announced A Dividend Of ₹2.50

A Look At The Intrinsic Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)

Aug 28
A Look At The Intrinsic Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)

We Think Glenmark Pharmaceuticals (NSE:GLENMARK) Is Taking Some Risk With Its Debt

Jul 03
We Think Glenmark Pharmaceuticals (NSE:GLENMARK) Is Taking Some Risk With Its Debt

A Look At The Fair Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)

May 28
A Look At The Fair Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)

Glenmark Pharmaceuticals (NSE:GLENMARK) Has A Somewhat Strained Balance Sheet

Mar 22
Glenmark Pharmaceuticals (NSE:GLENMARK) Has A Somewhat Strained Balance Sheet

Estimating The Fair Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)

Feb 14
Estimating The Fair Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)

An Intrinsic Calculation For Glenmark Pharmaceuticals Limited (NSE:GLENMARK) Suggests It's 37% Undervalued

Oct 12
An Intrinsic Calculation For Glenmark Pharmaceuticals Limited (NSE:GLENMARK) Suggests It's 37% Undervalued

Shareholders Will Probably Hold Off On Increasing Glenmark Pharmaceuticals Limited's (NSE:GLENMARK) CEO Compensation For The Time Being

Sep 21
Shareholders Will Probably Hold Off On Increasing Glenmark Pharmaceuticals Limited's (NSE:GLENMARK) CEO Compensation For The Time Being

Glenmark Pharmaceuticals (NSE:GLENMARK) Has Announced A Dividend Of ₹2.50

Aug 29
Glenmark Pharmaceuticals (NSE:GLENMARK) Has Announced A Dividend Of ₹2.50

We Think Glenmark Pharmaceuticals (NSE:GLENMARK) Can Stay On Top Of Its Debt

Jun 20
We Think Glenmark Pharmaceuticals (NSE:GLENMARK) Can Stay On Top Of Its Debt

There May Be Reason For Hope In Glenmark Pharmaceuticals' (NSE:GLENMARK) Disappointing Earnings

Jun 04
There May Be Reason For Hope In Glenmark Pharmaceuticals' (NSE:GLENMARK) Disappointing Earnings

An Intrinsic Calculation For Glenmark Pharmaceuticals Limited (NSE:GLENMARK) Suggests It's 27% Undervalued

May 05
An Intrinsic Calculation For Glenmark Pharmaceuticals Limited (NSE:GLENMARK) Suggests It's 27% Undervalued

If You Like EPS Growth Then Check Out Glenmark Pharmaceuticals (NSE:GLENMARK) Before It's Too Late

Mar 25
If You Like EPS Growth Then Check Out Glenmark Pharmaceuticals (NSE:GLENMARK) Before It's Too Late

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Glenn Saldanha rispetto agli utili di Glenmark Pharmaceuticals?
DataCompenso totaleStipendioGuadagni aziendali
Sep 30 2024n/an/a

-₹10b

Jun 30 2024n/an/a

-₹16b

Mar 31 2024₹169m₹135m

-₹19b

Dec 31 2023n/an/a

-₹8b

Sep 30 2023n/an/a

-₹1b

Jun 30 2023n/an/a

₹3b

Mar 31 2023₹162m₹130m

-₹2b

Dec 31 2022n/an/a

₹9b

Sep 30 2022n/an/a

₹8b

Jun 30 2022n/an/a

₹8b

Mar 31 2022₹158m₹130m

₹9b

Dec 31 2021n/an/a

₹10b

Sep 30 2021n/an/a

₹10b

Jun 30 2021n/an/a

₹10b

Mar 31 2021₹139m₹110m

₹10b

Dec 31 2020n/an/a

₹10b

Sep 30 2020n/an/a

₹9b

Jun 30 2020n/an/a

₹9b

Mar 31 2020₹122m₹91m

₹8b

Dec 31 2019n/an/a

₹7b

Sep 30 2019n/an/a

₹6b

Jun 30 2019n/an/a

₹8b

Mar 31 2019₹157m₹131m

₹9b

Dec 31 2018n/an/a

₹9b

Sep 30 2018n/an/a

₹9b

Jun 30 2018n/an/a

₹7b

Mar 31 2018₹162m₹134m

₹8b

Compensazione vs Mercato: La retribuzione totale di Glenn ($USD 1.95M ) è superiore alla media delle aziende di dimensioni simili nel mercato Indian ($USD 595.76K ).

Compensazione vs guadagni: La retribuzione di Glenn è aumentata nonostante l'azienda non sia redditizia.

AMMINISTRATORE DELEGATO

Glenn Saldanha (54 yo)

24yrs

Mandato

₹168,610,000

Compensazione

Mr. Glenn Mario Saldanha has been the Managing Director and Chief Executive Officer of Glenmark Pharmaceuticals Limited since 2000. Mr. Saldanha serves as Chairman at Ichnos Sciences Inc. Mr. Saldanha serv...

Gruppo dirigente

NomePosizioneMandatoCompensazioneProprietà
Glenn Saldanha
Chairman24yrs₹168.61m0.35%
₹ 1.5b
Cherylann Pinto
Executive Director of Corporate Services & Executive Directorno data₹60.84m0.27%
₹ 1.1b
V. Mani
Executive Directorless than a year₹102.12mNessun dato
Harish Kuber
Company Secretary & Compliance Officer7.9yrs₹5.53mNessun dato
Alind Sharma
President and Chief Human Resources Officer3yrsNessun datoNessun dato
Ulhas Dhuppad
President & Head of Global Pharmaceutical Development2.3yrsNessun datoNessun dato
Indrajit Bose
President & Chief Quality Officer1.3yrsNessun datoNessun dato
Brijlal Motwani
President & Global Head of Formulation Operations1.3yrsNessun datoNessun dato
Alok Malik
President & Business Head of India Formulations1.4yrsNessun datoNessun dato
Christoph Stoller
President and Business Head of Europe & Emerging Markets2yrsNessun datoNessun dato
Marc Kikuchi
President & Business Head of North Americaless than a yearNessun datoNessun dato
Ravi Agrawal
Investor Relations Officerno dataNessun datoNessun dato

1.7yrs

Durata media

55yo

Età media

Gestione esperta: Il team dirigenziale di GLENMARK non è considerato esperto (durata media 1.7 anni), il che suggerisce un nuovo team.

Membri del Consiglio di amministrazione

NomePosizioneMandatoCompensazioneProprietà
Glenn Saldanha
Chairman26.3yrs₹168.61m0.35%
₹ 1.5b
Cherylann Pinto
Executive Director of Corporate Services & Executive Director25.3yrs₹60.84m0.27%
₹ 1.1b
V. Mani
Executive Director6.7yrs₹102.12mNessun dato
Cyril Konto
Presidentless than a yearNessun datoNessun dato
Blanche Saldanha
Non Executive Director19.4yrs₹600.00k0.39%
₹ 1.6b
Rajesh Desai
Non-Executive Independent Director22.7yrs₹1.90m0.039%
₹ 160.3m
Vijayalakshmi Iyer
Independent Non-Executive Director1.9yrs₹1.20mNessun dato
Dipankar Bhattacharjee
Independent Non-Executive Director4.4yrs₹1.10mNessun dato
Sona Saira Ramasastry
Independent Non-Executive Director5.8yrs₹1.40mNessun dato

6.7yrs

Durata media

61yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di GLENMARK sono considerati esperti (durata media dell'incarico 6.7 anni).

Analisi aziendale e situazione dei dati finanziari

DatiUltimo aggiornamento (ora UTC)
Analisi dell'azienda2025/01/17 11:24
Prezzo dell'azione a fine giornata2025/01/17 00:00
Guadagni2024/09/30
Guadagni annuali2024/03/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

PacchettoDatiTempisticaEsempio Fonte USA *
Dati finanziari della società10 anni
  • Conto economico
  • Rendiconto finanziario
  • Bilancio
Stime di consenso degli analisti+3 anni
  • Previsioni finanziarie
  • Obiettivi di prezzo degli analisti
Prezzi di mercato30 anni
  • Prezzi delle azioni
  • Dividendi, scissioni e azioni
Proprietà10 anni
  • Top azionisti
  • Insider trading
Gestione10 anni
  • Team di leadership
  • Consiglio di amministrazione
Sviluppi principali10 anni
  • Annunci aziendali

* esempio per i titoli statunitensi, per quelli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più , cliccate qui.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su .

Fonti analitiche

Glenmark Pharmaceuticals Limited è coperta da 54 analisti. 12 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

AnalistaIstituzione
Sriraam RathiAnand Rathi Shares and Stock Brokers Limited
null nullAnand Rathi Shares and Stock Brokers Limited
Ganeshram JayaramanAvendus Spark